CXCL10 and Huntington disease: We confirmed that all eleven additional markers significantly peaked at day 1 in the Geneva cohort (Figure 2), with the largest fold increases reported in HD for CXCL11 [21.0 (95% CI, 15.1 to 29.2)], CXCL10 [14.2 (95% CI, 11 to 18.4)] and MCP2 [13.3 (95% CI, 11 to 16.1)] (Table 1).